ROIV ▲ +6.2% - Roivant Sciences Ltd.
$ROIV Roivant Sciences: Brepocitinib Meets Primary and All Key Secondary Endpoints in Two Phase 3 Trials for Non-Infectious Uveitis, sNDA Planned for H1 2027
21-OCT-2026 07:09 AM ET
Share this post
More filings for $ROIV
ROIV ▲ +4.7% - Roivant Sciences Ltd.Oct 21, 2026ROIV ▲ +4.7% - Roivant Sciences Ltd.Oct 21, 2026ROIV ▼ -1.3% - Roivant Sciences Ltd.Sep 23, 2026ROIV ▲ +2.5% - Roivant Sciences Ltd.Sep 8, 2026ROIV ▲ +2.6% - Roivant Sciences Ltd.Sep 6, 2026ROIV ▲ +1.6% - Roivant Sciences Ltd.Aug 27, 2026
View full $ROIV filing history →💬 Comments
Loading comments…
Leave a comment